The abstract is read at the publisher; the summary is JClub's.
Pathogenic SMAD2 variants modeled in human induced pluripotent stem cells disrupt podocyte development, causing failed arborizations and interdigitations and substantial albumin leakage on a glomerulus-on-a-chip.
- Why it matters: Congenital heart disease patients with SMAD2 variants often develop glomerulosclerosis, periglomerular fibrosis, and albuminuria, but it was unclear whether SMAD2 directly alters kidney cell fate and barrier function.
- What they did: Using CRISPR-based disease modeling, stem cell differentiation, and microfluidic organ-on-a-chip assays, the study tested how SMAD2 abrogation affects mesoderm/intermediate mesoderm patterning and later podocytogenesis.
- The result: Mutant intermediate mesoderm–derived podocytes showed impaired maturation, and reconstituted glomeruli-on-a-chip exhibited substantial albumin leakage, suggesting a link to glomerulopathy-like barrier defects.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.